This prospective, single-arm study examines the results of a 10-item questionnaire administered to women with breast cancer to gain patient perspective on self-reported chemotherapy-related adverse effects after the first and third cycles of chemotherapy.
This secondary analysis of clinical trial data examines older men assigned to intermittent androgen-deprivation therapy to determine frequency of bone, endocrine, cognitive, ischemic, and thrombotic events.
This population-based cohort study used national transplant registry data to assess whether solid-organ transplant recipients are at increased risk of cancer mortality compared with the general population.
This cohort study of 1090 men tests 9 DNA damage and repair pathways using 17 gene sets from prostatectomy samples to identify better biomarkers for patients at the highest risk to guide therapy intensification.
This cohort study of 1915 women with ovarian carcinoma assesses the frequency and importance of germline mutations in cancer-associated genes in ovarian cancer.
The TRAPEZE study compares the clinical effectiveness and cost-effectiveness of docetaxel alone or with strontium-89, zoledronic acid, or both in patients with bony metastatic castrate-refractory prostate cancer.
This population-based cohort study examines the comparative effectiveness of gonadotropin-releasing hormone agonists (GnRHa) vs bilateral orchiectomy in men with metastatic prostate cancer to determine whether GnRHa is associated with higher risks of several clinically relevant adverse effects.
This study investigates the long-term effect of axillary pathologic complete response on relapse-free and overall survival among women with breast cancer with cytologically confirmed axillary lymph node metastases treated with primary systemic chemotherapy.
This cohort study of 71 women with squamous cell carcinoma (SCC) of the cervix and vulva determines that recurrent copy gains of genes encoding the PD-1 (programmed cell death protein 1) ligands provide a genetic basis for PD-L1 (programmed cell death 1 ligand 1) expression in a subset of SCCs.
This retrospective analysis suggests that osimertinib may be more potent than rociletinib at clinical doses in patients exposed to more than 1 third-generation EGFR tyrosine kinase inhibitor.
This survey study assesses the prevalence of nonrecommended screening for prostate cancer and breast cancer in the United States.
This narrative review summarizes toxic effects of sorafenib in patients diagnosed with thyroid and other cancers.
A man in his 70s with rheumatoid arthritis and a 50-pack-year smoking history presented with a worsening unproductive cough, and workup identified a T2aN0M0 right upper lobe non–small-cell lung cancer; after treatment, he experienced abrupt onset of severe right shoulder pain. What is your diagnosis?
This Viewpoint evaluates prevention as a component of cancer research.
This Viewpoint explores recommendations for the inclusion of bisphosphonates in adjuvant therapy for postmenopausal breast cancer.
This Viewpoint asserts that the current model for cancer drug pricing in the United States is not sustainable, harms patients and families and the health care system, and calls for solutions that better balance access, affordability, and incentives to innovate.
This Viewpoint asks whether insurers are beginning to exclude stand-alone cancer centers in the form of “narrow networks” as a way to dissuade patients requiring expensive cancer care from choosing a particular health plan.
This Viewpoint discusses the components of successful end-of-life communication between patients and physicians.
This commentary discusses the results of the PREDIMED study, which asseed the effects of consumption of extra-virgin olive oil and the Mediterranean diet on reducing breast cancer risk.